spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare Industry News:  ADYNOVATE 

Biopharmaceuticals FDA

 News Release - August 1, 2016

Shire Announces FDA Approval of adynovate with BAXJECT III Reconstitution System

LEXINGTON, Massachusetts, August 1, 2016 -- (Healthcare Sales & Marketing Network) -- Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the U.S. Food and Drug Administration (FDA) has approved the BAXJECT III reconstitution system for ADYNOVATE [Antihemophilic Factor, (Recombinant), PEGylated]. The new system reduces the number of steps in the reconstitution process for hemophilia A patients and caregivers. ADYNOVATE and the diluent will be pre-packaged in the BAXJECT III reconstitution system.

"At Shire our focus is always on the patient, so we're pleased to provide our hemophilia A patients with a new option that will enable them to prepare their treatment with fewer steps," said Perry Sternberg, head of U.S. Commercial, Shire. "Streamlining the process may minimize opportunities for reconstitution errors, helping to ensure patients can get the full benefit of their treatment."

The BAXJECT III reconstitution system reduces the number of steps in the treatment process by two, compared to the previous process with the BAXJECT II Hi Flow Needleless transfer device. The BAXJECT III system with ADYNOVATE will be available to most customers in the fourth quarter of 2016, with a 2 mL diluent for the 250, 500, and 1000 IU potencies; and a 5 mL diluent for the 2000 IU potency.

ADYNOVATE, an extended circulating half-life recombinant Factor VIII (rFVIII) treatment built on the proven protein of ADVATE [Antihemophilic Factor (Recombinant)], was approved by the FDA in November 2015 for use in hemophilia A patients 12 years and older for on-demand treatment and control of bleeding and for prophylaxis to reduce the frequency of bleeding episodes. In early 2016, Baxalta, now part of Shire, filed for use in pediatric and surgical settings in the United States.

Important Information for ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated]

Indications

ADYNOVATE, [Antihemophilic Factor (Recombinant), PEGylated], is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency) for:
  • On-demand treatment and control of bleeding episodes
  • Routine prophylaxis to reduce the frequency of bleeding episodes
ADYNOVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

CONTRAINDICATIONS

ADYNOVATE is contraindicated in patients who have had prior anaphylactic reaction to ADYNOVATE, to the parent molecule (ADVATE), mouse or hamster protein, or excipients of ADYNOVATE (e.g. Tris, mannitol, trehalose, glutathione, and/or polysorbate 80).

WARNINGS & PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions are possible with ADYNOVATE. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with other recombinant antihemophilic factor VIII products, including the parent molecule, ADVATE. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, and pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

Neutralizing Antibodies

Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of ADYNOVATE. Monitor patients regularly for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests. Perform an assay that measures factor VIII inhibitor concentration if the plasma factor VIII level fails to increase as expected, or if bleeding is not controlled with expected dose.

ADVERSE REACTIONS

Common adverse reactions (=1% of subjects) reported in the clinical studies were headache and nausea.

For Full Prescribing Information, visit http://baxalta.com/assets/documents/ADYNOVATE_PI.pdf

Important Information for ADVATE [Antihemophilic Factor (Recombinant)]

Indications

ADVATE [Antihemophilic Factor (Recombinant)] is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:
  • Control and prevention of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes
ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

CONTRAINDICATIONS

ADVATE is contraindicated in patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product.

Source: Shire plc

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

Search: Shire plc 
Search: BAXJECT III 
Search: reconstitution system 
Healthcare Industry NewsFeed  


FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.